Multiple Assemblies exist for SMTL entry 9mr9
Crystal structure of AU-15330 in complex with the bromodomain of human BRM (SMARCA2) and pVHL:ElonginC:ElonginB; X-RAY DIFFRACTION 3.30 Å

	SMTL ID 9mr9.1 Ligands N-({4-[(6M)-3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl}acetyl)-3-methyl-L-valyl-(4R)-4-hydroxy-N-{(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide; 1,2-ETHANEDIOL Polypeptides Isoform Short of Probable global transcription activator SNF2L2; von Hippel-Lindau disease tumor suppressor; Elongin-C; Elongin-B Oligo-state hetero-1-1-1-1-mer
	SMTL ID 9mr9.2 Ligands N-({4-[(6M)-3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl}acetyl)-3-methyl-L-valyl-(4R)-4-hydroxy-N-{(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide; 1,2-ETHANEDIOL Polypeptides Isoform Short of Probable global transcription activator SNF2L2; von Hippel-Lindau disease tumor suppressor; Elongin-C; Elongin-B Oligo-state hetero-1-1-1-1-mer
	SMTL ID 9mr9.3 Ligands N-({4-[(6M)-3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl}acetyl)-3-methyl-L-valyl-(4R)-4-hydroxy-N-{(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide; GLYCEROL; 1,2-ETHANEDIOL Polypeptides Isoform Short of Probable global transcription activator SNF2L2; von Hippel-Lindau disease tumor suppressor; Elongin-C; Elongin-B Oligo-state hetero-1-1-1-1-mer
	SMTL ID 9mr9.4 Ligands N-({4-[(6M)-3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl}acetyl)-3-methyl-L-valyl-(4R)-4-hydroxy-N-{(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide Polypeptides Isoform Short of Probable global transcription activator SNF2L2; von Hippel-Lindau disease tumor suppressor; Elongin-C; Elongin-B Oligo-state hetero-1-1-1-1-mer
	SMTL ID 9mr9.5 Ligands N-({4-[(6M)-3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl}acetyl)-3-methyl-L-valyl-(4R)-4-hydroxy-N-{(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide; 1,2-ETHANEDIOL Polypeptides Isoform Short of Probable global transcription activator SNF2L2; von Hippel-Lindau disease tumor suppressor; Elongin-C; Elongin-B Oligo-state hetero-1-1-1-1-mer
	SMTL ID 9mr9.6 Ligands N-({4-[(6M)-3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl}acetyl)-3-methyl-L-valyl-(4R)-4-hydroxy-N-{(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide Polypeptides Isoform Short of Probable global transcription activator SNF2L2; von Hippel-Lindau disease tumor suppressor; Elongin-C; Elongin-B Oligo-state hetero-1-1-1-1-mer
	SMTL ID 9mr9.7 Ligands N-({4-[(6M)-3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl}acetyl)-3-methyl-L-valyl-(4R)-4-hydroxy-N-{(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide Polypeptides Isoform Short of Probable global transcription activator SNF2L2; von Hippel-Lindau disease tumor suppressor; Elongin-C; Elongin-B Oligo-state hetero-1-1-1-1-mer
	SMTL ID 9mr9.8 Ligands 1,2-ETHANEDIOL; N-({4-[(6M)-3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl}acetyl)-3-methyl-L-valyl-(4R)-4-hydroxy-N-{(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide Polypeptides Isoform Short of Probable global transcription activator SNF2L2; von Hippel-Lindau disease tumor suppressor; Elongin-C; Elongin-B Oligo-state hetero-1-1-1-1-mer